Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial

Circulation

Volumn 120, Issue 25, 2009, Pages 2550-2558

  Hlatky, Mark A ^a   Boothroyd, Derek B ^a   Melsop, Kathryn A ^a   Kennedy, Laurence ^b   Rihal, Charanjit ^c   Rogers, William J ^d   Venkitachalam, Lakshmi ^e   Brooks, Maria M ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angioplasty; Cost benefit analysis; Diabetes mellitus; Revascularization; Surgery

Indexed keywords

INSULIN;

ALBUMINURIA; ANGIOPLASTY; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; THERAPY DELAY; COMPARATIVE STUDY; ECONOMICS; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; INSULIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 73949135481     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.912709     Document Type: Article

References (26)

1. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360: 2503-2515
2. The BARI 2D Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J. 2008;156:528-536.
3. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol. 2006;97(suppl):9G-19G.
4. Hlatky MA, Melsop KA, Boothroyd DB. Economic evaluation of alternative strategies to treat patients with diabetes and coronary artery disease. Am J Cardiol. 2006;97(suppl):59G-65G.
5. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med. 1997;336:92-99.
6. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and utility in patients with coronary artery disease. Am Heart J. 2003;145:36-41.
7. Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation. 2004; 110:1960-1966.
8. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
9. Sculpher MJ, Smith DH, Clayton T, Henderson RA, Buxton MJ, Pocock SJ, Chamberlain DA; Randomized Intervention Treatment of Angina (RITA-2) Trial. Coronary angioplasty versus medical therapy for angina: health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. Eur Heart J. 2002;23:1291-1300.
10. Favarato D, Hueb W, Gersh BJ, Soares PR, Cesar LA, da Luz PL, Oliveira SA, Ramires JA. Relative cost comparison of treatments for coronary artery disease: the first year follow-up of MASS II study. Circulation. 2003;108(suppl II):21-23.
11. Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P, Osswald S, Kaiser C, Grädel C, Estlinbaum W, Rickenbacher P, Pfisterer M; Trial of Invasive versus Medical therapy in the Elderly (TIME) Investigators. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J. 2004;25: 2195-2203. (Pubitemid 39592420)
12. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascu-larization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med. 1990;113:852-871.
13. Sculpher MJ, Petticrew M, Kelland JL, Elliott RA, Holdright DR, Buxton MJ. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess. 1998;2(10):i-iv, 1-176.
14. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation. 1982;66(suppl III):56-66.
15. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King S III, Frye RL; BARI 2D Study Group. Baseline coronary angiographic findings in the Bypass Angioplasty Re-vascularization Investigation 2 Diabetes trial (BARI 2D). Am J Cardiol. 2009;103:632-638.
16. Gray A, Clarke P, Farmer A, Holman R. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ. 2002;325:860.
17. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48:868-877.
18. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diab Care. 2008;31:1510-1515.
19. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract. 2000;48:201-210.
20. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182-189
21. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;2542-2551.
22. Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and ros-iglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess. 2004;8(13):iii, ix-x, 1-91.
23. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
24. Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in type 2 diabetes in the UK. Diabet Med. 2007;24:982-1002. (Pubitemid 47301635)
25. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
26. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.